Natl Sci Open
Volume 1, Number 1, 2022
Special Topic: COVID-19: Virus, Immunity and Vaccines
Article Number 20220008
Number of page(s) 6
Section Life Sciences and Medicine
Published online 25 March 2022
  • Zhou P, Yang XL, Wang XG et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579 : 270- 273. [Article] [CrossRef] [PubMed] [Google Scholar]
  • Chiu NC, Chi H, Tu YK et al. To mix or not to mix? A rapid systematic review of heterologous prime–boost covid-19 vaccination. Expert Rev Vaccines 2021; 20 : 1211- 1220. [Article] [CrossRef] [PubMed] [Google Scholar]
  • Logunov DY, Dolzhikova IV, Shcheblyakov DV et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 2021; 397 : 671- 681. [Article] [CrossRef] [PubMed] [Google Scholar]
  • Schmidt T, Klemis V, Schub D et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med 2021; 27 : 1530- 1535. [Article] [CrossRef] [PubMed] [Google Scholar]
  • Tenbusch M, Schumacher S, Vogel E et al. Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2. Lancet Infect Dis 2021; 21 : 1212- 1213. [Article] [CrossRef] [PubMed] [Google Scholar]
  • Borobia AM, Carcas AJ, Pérez-Olmeda M et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet 2021; 398 : 121- 130. [Article] [CrossRef] [PubMed] [Google Scholar]
  • Liu X, Shaw RH, Stuart ASV et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet 2021; 398 : 856- 869. [Article] [CrossRef] [PubMed] [Google Scholar]
  • Greinacher A, Thiele T, Warkentin TE et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 2021; 384 : 2092- 2101. [Article] [CrossRef] [PubMed] [Google Scholar]
  • Cao Y, Hao X, Wang X et al. Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine. Cell Res 2022; 32 : 107- 109. [Article] [CrossRef] [PubMed] [Google Scholar]
  • Ai J, Zhang H, Zhang Q et al. Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and variants of concern. Cell Res 2022; 32 : 103- 106. [Article] [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
  • Keskin AU, Bolukcu S, Ciragil P et al. SARS‐CoV‐2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two‐dose CoronaVac vaccine regimen. J Med Virol 2022; 94 : 39- 41. [Article] [CrossRef] [PubMed] [Google Scholar]
  • Abdool Karim SS, de Oliveira T New SARS-CoV-2 variants — clinical, public health, and vaccine implications. N Engl J Med 2021; 384 : 1866- 1868. [Article] [CrossRef] [PubMed] [Google Scholar]
  • Barros-Martins J, Hammerschmidt SI, Cossmann A et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med 2021; 27 : 1525- 1529. [Article] [CrossRef] [PubMed] [Google Scholar]
  • World Health Organization. COVID-19 vaccine tracker and landscape. https://wwwwhoint/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. 2021. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.